That's a lot of questions. I'll try to go with a few, hopefully, can pick up where I missed. Q3 unscheduled billings was 28% growth year over year. So that is outstanding. Scheduled billings growth in Q3 came as expected. Was below 20% range. The unscheduled billings in Q4 and the guidance that we gave is 25% growth year over year. So, you know, the business is doing very well, and it's consistent with what we said at the beginning of the year when we called out scheduled versus unscheduled billings. It's pretty much worked up almost exactly what we said. So, yeah, we're really, you know, proud, you know, of how we communicated that to the street and how the performance is happening in the second half of the year. Related to the NRR rate, it is 114%, but that is outstanding. So from my perspective, you know, only look, we've said this before. We only look at it, you know, once every quarter. Right now, we're talking to our investor call. See, the key thing, I think, you know, is that you look at what we have and the platform that we created, and the expansion of the emerging products. You know, we've talked about that the emerging products, you know, is expanding. So we're expecting emerging products to, you know, be in the mid-twenty to high 20% range. Know, for this year. And the reason for that is that we're expanding the products. Those are all new products that come out. You know, DSPM, GenAI, you know, in the DLP products. So I think, you know, Jay called out, we're a technology company. We're an innovation company. I mean, we are at the size that we have a, you know, very large, you know, revenue and recurring revenue and RPO. But at the heart, Zscaler is a technology company that's at the forefront to continue to really, I think, exploit this market as no other company can.